GlassScriptPhysician profile
Marc R Kappelman
NPI 1144328915
$997.95
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $99.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $315.83 | 2019 | |
| Hologic Sales and Service, LLC | $140.97 | 2019 | |
| Amag Pharmaceuticals, INC. | $122.53 | 2019 | |
| Astellas Pharma US INC | $100.00 | 2019 | |
| Allergan, INC. | $99.99 | 2020 | |
| Merck Sharp & Dohme LLC | $96.80 | 2019 | |
| Abbvie INC. | $81.95 | 2019 | |
| Coopersurgical, INC. | $14.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.19 | 2019 | |
| Exeltis, USA INC. | $11.73 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Kappelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.